Pro-Arc Diagnostics

Pro-Arc Diagnostics develops a blood test to identify patients at risk of Progressive Multifocal Leukoencephalopathy (PML). This diagnostic targets the John Cunningham Virus (JCV), which can cause severe complications in individuals with compromised immune systems, particularly those on powerful multiple sclerosis therapies. The company’s technology provides crucial risk assessment for treatment decisions.

James Sorrell, Michelle Faits, and Dana Watt co-founded Pro-Arc Diagnostics in 2015. Their insight originated from the critical need for precise diagnostics to stratify PML risk. This enables patients with conditions like multiple sclerosis to access effective therapies more safely, addressing a significant challenge in personalized medical care.

The company primarily serves patients receiving potent treatments, especially for multiple sclerosis, and their clinicians. Pro-Arc Diagnostics’ mission is to expand access to advanced, industry-leading therapies by supplying essential diagnostic insights. This approach aims to mitigate treatment-related risks, thereby improving patient safety and enhancing the effectiveness of medical interventions.

High-Level Overview

Pro-Arc Diagnostics is a St. Louis, Missouri-based molecular diagnostics startup founded in 2014, developing JCVerify, a next-generation laboratory test to screen for the John Cunningham (JC) virus, which causes Progressive Multifocal Leukoencephalopathy (PML)—a fatal brain infection affecting patients on certain therapies, particularly for multiple sclerosis (MS).[1][2][3][4] The company serves patients at risk from monoclonal antibody treatments like natalizumab (Tysabri), enabling doctors to identify high-risk individuals, monitor PML risk, and safely expand access to these therapies.[1][2][4] It solves the critical gap where no prior method existed to predict PML vulnerability, potentially preventing thousands of deaths annually while restoring promise to industry-leading MS treatments.[1][2]

As a women-led biotech (with key executives including CEO Michelle Faits and CSO Dana Watt), Pro-Arc emerged from Washington University research and joined accelerators like Springboard's health innovation hub, showing early traction through university entrepreneurship support.[2][4][5]

Origin Story

Pro-Arc Diagnostics spun out from Washington University in St. Louis around 2014-2017, launched by Dana Watt (Co-Founder and Chief Scientific Officer), a postdoctoral fellow in entrepreneurship at the university.[1][2][5] Watt, with a neuroscience background from the Cavalli Lab, identified the need for PML risk prediction during her research on the JC virus, which causes PML in immunocompromised patients—especially those on MS drugs.[1][3] Pivotal early moments included Watt's biotech launch announcement in the lab's 2019 news, her close collaboration with the university's entrepreneurship center, and the company's selection into Springboard's women-led healthcare cohort in 2017.[1][4][5]

Leadership expanded with Michelle Faits as CEO and Christopher Bethel as Chief Scientific Officer (a scientist from Sigma-Aldrich), blending academic roots with industry expertise.[2] A 2015 Rice Alliance video highlights their pitch, marking public visibility.[8]

Core Differentiators

• Targeted JC Virus Screening: JCVerify offers a novel, precise molecular diagnostic for PML risk—unlike prior tests, it identifies at-risk patients before symptoms, allowing tailored treatment and averting fatal outcomes.[1][3][4]
• Focus on MS Therapy Access: Enables safer use of high-efficacy drugs like natalizumab by stratifying patients, directly addressing a clinical bottleneck in neurology.[2][4]
• Academic-to-Commercial Translation: Strong ties to Washington University provide validated science and entrepreneurship resources, accelerating development from lab discovery to market.[1][5]
• Women-Led Expertise: Combines clinical (Faits), scientific (Watt, Bethel), and operational strengths in a compact team, fostering agile innovation in diagnostics.[2][4]

Role in the Broader Tech Landscape

Pro-Arc rides the precision medicine wave in neurology and immunotherapy, where companion diagnostics unlock blockbuster drugs by mitigating rare but severe risks like PML—exemplified by natalizumab's black-box warnings that limited its use.[2][4] Timing aligns with surging MS prevalence (1M+ US cases) and biologics expansion, amplified by post-2020 demand for personalized therapies amid aging populations and autoimmune disease rises.[1][3] Market forces favor it: diagnostics market growth (projected $100B+ globally), regulatory emphasis on patient stratification (FDA companion diagnostic approvals), and biotech hubs like St. Louis gaining traction via university spinouts.[5] Pro-Arc influences the ecosystem by pioneering PML prediction, potentially standardizing risk screening and enabling broader monoclonal antibody adoption, while exemplifying women-led spinouts bridging academia and health tech.[4][5]

Quick Take & Future Outlook

Pro-Arc's validated science positions it for clinical validation milestones, partnerships with MS pharma giants (e.g., Biogen), and FDA clearance as a companion diagnostic—key to commercialization by 2026-2028.[1][4] Trends like AI-enhanced diagnostics and value-based care will amplify its impact, expanding to other JC virus-linked risks in oncology/immunology. Its influence may evolve from niche PML innovator to broader neurology diagnostics player, scaling via acquisitions or funding amid biotech's precision shift—ultimately fulfilling its mission to safeguard therapies that transform lives.[2][5] This St. Louis gem underscores how targeted tests can revive high-stakes treatments, echoing its origin in solving an unseen killer.